SFC–MS/MS for identification and simultaneous estimation of the isoniazid and pyrazinamide in its dosage form

Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review

Formulations containing more than one active ingredient are increasingly gaining popularity due to advantages with regard to patient convenience as well as reduced cost of production, packaging, and transportation. Such fixed-dose combinations (FDCs) demand for enhanced analytical methodologies and tools to efficiently achieve quality control of these complex products as compared to the conventional products containing only one active constituent. Highly efficient analytical methods can measure multiple constituents at once, improving their quality control. This review article discusses the challenges in the development of such methods due to the similarities or differences in the chemical identity of the participating drug molecules in an FDC. The latest developments in multiple analyte determination using various analytical techniques (HPLC, LC-MS, NMR, IR, powder XRD and DSC) are discussed, with a focus on special considerations in each case. The article discusses challenges with sample preparation of complex FDC products, and the use of Chemometrics and Quality by Design to develop efficient analytical methods. Lastly, an equation-based approach is proposed and demonstrated to arrive at a parameter referred to as "percentage efficiency gain" that would be useful in directly accessing the relevance and commercial benefits of a simultaneous method vis-a-vis separate methods for individual components.

A DFT study on non-enzymatic degradations of anti-tuberculosis drug isoniazid

CONTEXT

Isoniazid (INH) is one of the medications most used for tuberculosis (TB) treatment. However, long-term continuous therapy can cause hepatotoxicity and peripheral neuritis. The degradation of INH is an important aspect of the research in the field of drug stability as well as drug formulation for controlling release. It is thought that tautomerization, hydrolysis as well as nucleophilic substitutions can cause decrease in INH as non-enzymatic degradation. Therefore, it is crucial to understand the mechanisms and energies of the major reactions in order to provide reference for future drug formulation and application. This study is an effort to understand the kinetic and thermodynamic properties of the non-enzymatic degradation reactions. The chemical reaction phenomena are investigated using the density functional theory (DFT) method. This study shows that major degradation of INH can be done via tautomerization followed by hydrolysis. The general trends in nucleophilic degradation presented here are consistent with experimental pKa of nucleophiles.

METHODS

All DFT calculations were performed using the Gaussian Software Packages (Gaussian 09 revision B.01 and GaussView 5.0.8). MOLEKEL 4.3 software was utilized to visualize the molecular graphics of all relevant species. The optimized molecular geometries were calculated using B3LYP/6-311 + G(d,p) level in the gas phase. The IEF-PCM/B3LYP/6-311 + G(d,p) level was selected for single-point and frequency calculations in aqueous media.

A simple and rapid method to simultaneously analyze ciclesonide and its impurities in a ciclesonide metered-dose inhaler using on-line supercritical fluid extraction/supercritical fluid chromatography/quadrupole time-of-flight mass spectrometry

A simple and rapid on-line SFE/SFC/quadrupole TOF-MS method to simultaneously analyze active pharmaceutical ingredients and impurities from metered-dose inhalers (MDIs) was developed using ciclesonide MDI (CIC-MDI) as an example. CIC-MDI, as drug Alvesco®, has been approved for the treatment of bronchial asthma, and its major impurities are listed in the European Pharmacopoeia and in the supplementary package inserts of Alvesco® (called as "Pharmaceutical interview form" in Japan). In the developed method, CIC-MDI was manually sprayed only once on a glass disc prior to the SFE/SFC/quadrupole TOF-MS. In the SFE, CIC and its impurities and other impurities having various polarities and hydrophobicity, were extracted in 3.5 min and subsequently separated on a CHIRALPAK IE-3 column to be detected by quadrupole TOF-MS in 6.5 min. This method would be applicable to the analysis of other inhalable pharmaceutical products whose sample preparation requires complicated procedures, as well as to the analysis of general pharmaceutical products for profiling impurities.

Ultra-high performance supercritical fluid chromatography in impurity control II: Method validation

In our previous study we proposed a screening approach using ultra-high performance supercritical fluid chromatography for the determination of 10 pharmaceutical quality control mixtures. Most of resulting methods offered baseline separation of all analytes. However, some of these methods had to be further optimized to ensure their successful validation and applicability to impurity control in drug substance and drug products. Several challenges occurred during the optimization including: (i) the necessity of the resolution of active pharmaceutical ingredient and following impurity equaling at least 3, which was especially difficult to achieve for mixtures of structurally close compounds, (ii) unrepeatable elution of compounds eluting close to the dead volume or at the end of the gradient elution, and (iii) shifts in retention times due to the column aging and effects of additive. The most frequent optimization adjustments involved changes in gradient program. Other adjustments such as the substitution of Viridis UPC² HSS C18 SB column with a slightly different Acquity UPLC HSS C18 SB column, the addition of acetonitrile in the modifier, and the column coupling also led to beneficial changes in selectivity. Subsequently, validation of all 10 methods was carried out to prove the applicability of ultra-high performance supercritical fluid chromatography methods for the impurity control in pharmaceuticals. Parameters recommended by ICH guidelines Q2 and Q3 including specificity, linearity, range, lower and upper limit of quantification, limit of detection, accuracy, and precision were examined. In addition, intermediate precision and the accuracy profiles were determined for selected methods. Overall, only two impurities did not meet the validation criteria due to low resolution and low sensitivity, respectively. Only identification threshold and not reporting threshold was met for this impurity.